Results 51 to 60 of about 8,708 (251)

Extended-spectrum beta-lactamase-producing enterobacteriaceae : epidemiology and dynamics of fecal carriage [PDF]

, 2013
ESBL-producing Enterobacteriaceae (EPE) has become a major cause of community acquired urinary tract infection (UTI), and fecal carriage of EPE is emerging worldwide.
Titelman, Emilia
core   +1 more source

Treatment of infections caused by multidrug-resistant Gram-negative bacteria:Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party [PDF]

, 2018
The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and ...
Enoch, David A, Hawkey, Peter M, Livermore, David M, McNulty, Cliodna A M, Otter, Jonathan A, Warren, Roderic E, Wilson, A Peter R   +6 more
core   +1 more source

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-2016 [PDF]

, 2017
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use.
Doumith, Michel, Hill, Robert, Hopkins, Katie L, Livermore, David M, Meunier, Danièle, Pike, Rachel, Staves, Peter, Woodford, Neil   +7 more
core   +1 more source

Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA).

Journal of Global Antimicrobial Resistance
OBJECTIVES Antibacterial-resistant gram-negative hospital-acquired infections result in significant morbidity and mortality. In clinical trials, ceftolozane/tazobactam (C/T) has been effective against these infections; however, real-world findings are ...
A. Soriano, David L Paterson, Florian Thalhammer, S. Kluge, Pierluigi Viale, Alexandre H. Watanabe, M. Allen, B. Akrich, Stephanie Wirbel, E. Obi, Emre Yücel, Sundeep Kaul   +11 more
semanticscholar   +1 more source

Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia.

Clinical Infectious Diseases
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ...
Sunish Shah, Ellen G. Kline, G. Haidar, Kevin M. Squires, J. Pogue, E. McCreary, Justin Ludwig, L. Clarke, Madison E. Stellfox, D. Van Tyne, R. K. Shields   +10 more
semanticscholar   +1 more source

Potential of high-dose cefepime/tazobactam against multi-resistant Gram-negative pathogens [PDF]

, 2017
Background: Early β-lactamase inhibitors were combined with established penicillins, but different combinations may be more appropriate to counter current β-lactamase threats, with development facilitated by the US Generating Antibiotic Incentives Now ...
Livermore, David M, Mushtaq, Shazad, Turner, Simon J, Warner, Marina, Woodford, Neil   +4 more
core   +1 more source

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

Brazilian Journal of Infectious Diseases, 2017
This study evaluated the in vitro activity of ceftolozane-tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections.
Michael A. Pfaller, Dee Shortridge, Helio S. Sader, Ana Gales, Mariana Castanheira, Robert K. Flamm   +5 more
doaj   +1 more source

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

International Journal of Infectious Diseases, 2017
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom, Hashim Elsayed, Karen Lawlor, Laila AbdelWareth, Rania El-Lababidi, Lysettee Cardona, Mohammad Mooty, Maria-Fernanda Bonilla, Ahmad Nusair, Imran Mirza   +9 more
doaj   +1 more source

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) [PDF]

, 2013
Ceftolozane/tazobactam, a novel antimicrobial agent with activity against Pseudomonas aeruginosa (including drug-resistant strains) and other common Gram-negative pathogens (including most extended-spectrum-beta-lactamase [ESBL]-producing ...
Farrell, David J., Flamm, Robert K., Jones, Ronald N., Sader, Helio S.   +3 more
core   +2 more sources

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source